Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients

PA Murray, SL Koletar, I Mallegol, J Wu… - Clinical …, 1997 - Elsevier
This multicenter, open-label, third-party—masked trial compared the efficacy and safety of
itraconazole oral solution (200 mg once daily) and clotrimazole troches (10 mg five times
daily) in a population of immunocompromised subjects composed primarily of patients with
human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). Patients
were treated for 14 days; patients who exhibited a clinical response were followed up for an
additional month to document the occurrence of relapse. Efficacy was judged by changes …
以上显示的是最相近的搜索结果。 查看全部搜索结果